Abstract: The present disclosure related in general to methods of treating cancer by interfering with the interaction of metadherin with Staphylococcal nuclease domain-containing 1 (SND1) using peptides or other compounds that inhibit the binding of SND1 with metadherin and inhibit the activity of the MTDH-SND1 complex in tumor cells.

Abstract: The present invention relates to novel compounds which are aryl hydrocarbon receptor (AHR) ligands and uses thereof. Methods of activating the AHR receptor in a subject are also provided.

Abstract: The present disclosure related in general to methods of treating cancer by interfering with the interaction of metadherin with Staphylococcal nuclease domain-containing 1 (SND1) using peptides or other compounds that inhibit the binding of SND1 with metadherin and inhibit the activity of the MTDH-SND1 complex in tumor cells.

Abstract: The present disclosure related in general to methods of treating cancer by interfering with the interaction of metadherin with Staphylococcal nuclease domain-containing 1 (SND1) using peptides or other compounds that inhibit the binding of SND1 with metadherin and inhibit the activity of the MTDH-SND1 complex in tumor cells.

Abstract: The present invention relates to novel compounds which are aryl hydrocarbon receptor (AHR) ligands and uses thereof.

Abstract: The present disclosure related in general to methods of treating cancer by interfering with the interaction of metadherin with Staphylococcal nuclease domain-containing 1 (SND1) using peptides or other compounds that inhibit the binding of SND1 with metadherin and inhibit the activity of the MTDH-SND1 complex in tumor cells.

Abstract: Atomic coordinates for human serine/threonine protein phosphotase 2A (PP2A) core, as well as methods for using these atomic coordinates to prepare inhibitors of PP2A and inhibitors prepared using such methods are provided herein. A biochemical analysis of the interactions of PP2A core is also provided. Compositions including mimetics and small molecules of the invention and, optionally, secondary agents may be used to treat disorders in which PP2A activity plays a contributing role.

Abstract: Atomic coordinates for human serine/threonine protein phosphotase 2A (PP2A) holoenzyme, as well as methods for using these atomic coordinates to prepare inhibitors of PP2A and inhibitors prepared using such methods are provided herein. A biochemical analysis of the interactions of PP2A holoenzyme is also provided. Compositions including mimetics and small molecules of the invention and, optionally, secondary agents may be used to treat disorders in which PP2A activity plays a contributing role.

Abstract: Embodiments of the present invention relate to atomic coordinates for PME-1 alone or in complex with PP2A, as well as methods for using these atomic coordinates to prepare inhibitors of PME-1 and/or PP2A and inhibitors prepared using such methods. Further embodiments relate to biochemical analyses of the interactions of PME-1 alone or in complex with PP2A. Further embodiments relate to compositions including mimetics and small molecules, optionally, secondary agents, which may be used to treat disorders in which PME-1 and/or PP2A activity plays a contributing role.

Abstract: The disclosure relates to modulation of protein phosphorylation, including information derived from the structures and activities of the proteins designated protein phosphatase 2A (PP2A) and PP2A methyl esterase. The disclosure contained herein provides compounds and methods for identification of compounds that antagonize the function of PME, and thus reduce levels of PP2A demethylation activity. Over-expression or gain-of-function of PME contributes to a range of diseases such as cancer, thus inhibition of PME by antagonists may provide a strategy for therapeutic intervention.

Abstract: The disclosure relates to modulation of protein phosphorylation, including information derived from the structures and activities of the proteins designated protein phosphatase 2A (PP2A) and PP2A methyl esterase. The disclosure contained herein provides compounds and methods for identification of compounds that antagonize the function of PME, and thus reduce levels of PP2A demethylation activity. Over-expression or gain-of-function of PME contributes to a range of diseases such as cancer, thus inhibition of PME by antagonists may provide a strategy for therapeutic intervention.

Abstract: Compositions containing a knob attached to a specific site of a protein and methods of producing and using these compositions are disclosed. The compositions comprise a knob, a tail portion and a protein portion. The protein portion contains a substituted cysteine residue at the desired location of labeling. The tail portion is located at the terminal end of the protein portion. The knob is linked to the end of the tail portion and contains a cysteine residue. The substituted cysteine residue on the protein portion and the cysteine residue on the knob form a disulfide bond, thereby tagging the protein portion at the desired site with the knob.